A Hangover Under 177 Lu-PSMA-617 Therapy : A Red Flag for Brain 68 Ga-PSMA-11 PET/MRI?
Fiche publication
Date publication
juin 2024
Journal
Clinical nuclear medicine
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BENDER Laura, Dr SOMME François, Dr BUND Caroline
Tous les auteurs :
Poterszman N, Somme L, Bund C, Hutt E, Somme F
Lien Pubmed
Résumé
Leptomeningeal carcinomatosis in prostate cancer is extremely rare. Because of the low overall penetration of drugs into the brain and the prolonged survival of castration-resistant prostate cancer (CRPC) patients, a special attention should be paid to the appearance of neurological symptoms in long-term CRPC survivors. A patient suffering from a CRPC with bone metastases underwent 4 cycles of 177 Lu-PSMA (prostate-specific membrane antigen)-617. Starting from the third cycle, he reported an increasing feeling of a permanent hangover. A 68 Ga-PSMA-11 brain PET/MRI was carried out after the fourth cycle. It revealed intraparenchymatous brain metastases with intense uptake and evidences of leptomeningeal carcinomatosis.
Mots clés
Humans, Male, Gallium Isotopes, Gallium Radioisotopes, Magnetic Resonance Imaging, Lutetium, Positron-Emission Tomography, Dipeptides, Heterocyclic Compounds, 1-Ring, Multimodal Imaging, Edetic Acid, analogs & derivatives, Aged, Prostatic Neoplasms, Castration-Resistant, diagnostic imaging, Radioisotopes, Brain Neoplasms, diagnostic imaging, Brain, diagnostic imaging, Prostate-Specific Antigen
Référence
Clin Nucl Med. 2024 06 1;49(6):582-583